Company intelligence / Profile preview

Proximity Therapeutics

San Francisco, California, United Statesgeneralproximity.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

General Proximity has emerged from stealth with $16 million in seed funding to develop next-generation induced proximity medicines for undruggable targets using its proprietary OmniTAC platform. The company’s first wave of drug candidates targets oncology, cardiometabolic disease, neurodegeneration, and longevity. No clinical results have been reported yet as programs are at the preclinical stage.

Therapeutic areas: OncologyCardiovascularNeurologyOther
Modalities: Small molecules (specifically induced proximity medicines)
Industry: Biotech

Partnerships

Johnson & Johnson JLabs biotech incubator participant

Beyond the preview

Go deeper on Proximity Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proximity Therapeutics.

Explore the full profile